Chronic phase of Chagas disease: why should it be treated? A comprehensive review.

Abstract

The pathogenesis and evolutive pattern of Chagas disease suggests that the chronic phase should be more widely treated in order to (i) eliminate Trypanosoma cruzi and prevent new inflammatory foci and the extension of tissue lesions, (ii) promote tissue regeneration to prevent fibrosis, (iii) reverse existing fibrosis, (iv) prevent cardiomyopathy, megaoesophagus and megacolon and (v) reduce or eliminate cardiac block and arrhythmia. All cases of the indeterminate chronic form of Chagas disease without contraindications due to other concomitant diseases or pregnancy should be treated and not only cases involving children or recently infected cases. Patients with chronic Chagas cardiomyopathy grade II of the New York Heart Association classification should be treated with specific chemotherapy and grade III can be treated according to medical-patient decisions. We are proposing the following new strategies for chemotherapeutic treatment of the chronic phase of Chagas disease: (i) repeated short-term treatments for 30 consecutive days and interval of 30-60 days for six months to one year and (ii) combinations of drugs with different mechanisms of action, such as benznidazole + nifurtimox, benznidazole or nifurtimox + allopurinol or triazole antifungal agents, inhibition of sterol synthesis.

• Authors: José Rodrigues Coura, José Borges-Pereira
• Journal: Memorias do Instituto Oswaldo Cruz (Mem Inst Oswaldo Cruz) Vol. 106 Issue 6 Pg. 641-5 (Sep 2011) ISSN: 1678-8060 [Electronic] Brazil
• PMID: 22012216 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Trypanocidal Agents

Topics

• Animals
• Chagas Disease (complications, drug therapy, pathology)
• Chronic Disease
• Disease Progression
• Drug Administration Schedule
• Drug Therapy, Combination
• Female
• Humans
• Pregnancy
• Trypanocidal Agents (administration & dosage)